HIV-2 (AA 390-702) antibody

Catalog No. ABIN111771

Cited in 1 publication. The Mouse Monoclonal anti-HIV-2 antibody (Clone BDI411) (ABIN111771) specifically detects HIV-2 in WB, EIA and IP. The antibody is reactive with Human Immunodeficiency Virus (HIV) samples.

Quick Overview for HIV-2 (AA 390-702) antibody (ABIN111771)

Target: HIV-2

Reactivity: Human Immunodeficiency Virus (HIV)

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Western Blotting (WB), Enzyme Immunoassay (EIA), Immunoprecipitation (IP)

Clone: BDI411

Product Details

Binding Specificity: AA 390-702

Purification: Protein G Chromatography.

Immunogen: Recombinant gp36, amino acids 390-702 (Art. No. BIN07)

Isotype: IgG2a

Application Details

Application Notes: Suitable for use in Western blot (1: 1,000), ELISA (1: 500) and Immunoprecipitation.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 1.0 mg/mL

Buffer: 1X PBS, pH 7.2 containing 0.01 % Sodium Azide as preservative.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

References

Dufrasne, Lucchetti, Martin, André, Dessilly, Kabamba, Goubau, Ruelle: "Modulation of the NF-κB signaling pathway by the HIV-2 envelope glycoprotein and its incomplete BST-2 antagonism." in: Virology, Vol. 513, pp. 11-16, (2017) (PubMed).

Target Details

Target: HIV-2

Target Type: Virus

Background: HIV2 infections at present, are predominantly found in west Africa where it is the dominant form of HIV. Both HIV1 and HIV2 have the same modes of transmission and are associated with similar opportunistic infections and AIDS. In persons infected with HIV2, immunodeficiency seems to develop more slowly and to be milder, but as the disease advances, HIV2 infectiousness seems to increase. Little is known about the best approach to the clinical treatment and care of patients infected with HIV2. Some drugs used to treat HIV1 are ineffective. HIV1 and HIV2 have similar gag (viral core) and pol (polymerase) regions, they have relatively dissimilar env (envelope) regions. Owing to this lack of homology in the envelope region, there is little serologic cross-reactivity of the antibodies directed against the envelope antigens of both HIV1 and HIV2. The env gp36 ectodomain is highly conserved and elicits a type-specific antibody response. Hence, most licensed diagnostic assays incorporate gp36-derived antigens to detect HIV2 specific antibodies. It is becoming important to differentiate between single infection with either HIV1 or HIV2 and dual infection.Synonyms: HIV2, Human immunodeficiency virus type 2